| Japanese |
|---|
| Title | 薬剤性腎障害ラットにおける99mTc-DMSA腎シンチグラフィの有用性に関する研究 - II. シスプラチン腎障害に関して - |
|---|
| Subtitle | ≪原著≫ |
|---|
| Authors | 山田雅文* |
|---|
| Authors(kana) | |
|---|
| Organization | *愛媛大学医学部放射線医学教室 |
|---|
| Journal | 核医学 |
|---|
| Volume | 28 |
|---|
| Number | 4 |
|---|
| Page | 347-354 |
|---|
| Year/Month | 1991/4 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」シスプラチン(CDDP)による腎障害ラットにおいてクレアチニン・クリアランス(Ccr)と比較することで, 99mTc-DMSAシンチグラフィによる腎摂取率測定の腎機能評価としての有用性を検討した. CDDP 1.8mg/kg/dayを3, 5, 7, 9日間毎日腹腔内投与し, その翌日に99mTc-DMSA腎摂取率とCcrを測定した. Ccrは5日投与群で有意に低下(p<0.01)したのに対し99mTc-DMSA腎摂取率は7日投与群で初めて有意に低下した(p<0.01). CDDP 3.6mg/kg/dayを第1, 2, 15, 16日目に腹腔内投与し, 5, 8, 11, 15, 20, 23, 26, 30日目に同様の測定を行ったが, Ccrは5日目群で有意に低下(p<0.01)し15日目群ではコントロール値に回復したのに対し, 99mTc-DMSA腎摂取率は8, 11, 15日目群で有意に低下した(p<0.01), 99mTc-DMSAシンチグラフィにより測定された腎摂取率はCcrとは異なる腎機能を反映する有用な指標と考えられた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 99mTc-dimercaptosuccinic acid (99mTc-DMSA), Drug-induced nephrotoxicity, Cis-Dichlorodiammineplatinum (II) (CDDP), Absolute renal uptake. |
|---|
| English |
|---|
| Title | Assessment of 99mTc-DMSA Renoscintigraphy and Uptake Compared with Creatinine Clearance in Rats with Drug-Induced Nephrotoxicity - II. Cisplatin-Induced Nephrotoxicity - |
|---|
| Subtitle | - Original Articles - |
|---|
| Authors | Masafumi YAMADA |
|---|
| Authors(kana) | |
|---|
| Organization | Department of Radiology, Ehime University School of Medicine |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 28 |
|---|
| Number | 4 |
|---|
| Page | 347-354 |
|---|
| Year/Month | 1991/4 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] For evaluation of technetium-99m dimercaptosuccinic acid (99mTc-DMSA) renal uptake as an absolute renal function, 99mTc-DMSA uptake was compared with endogenous creatinine clearance (Ccr) in cisplatin-induced nephrotoxicity. At first, Male Wistar rats were given intraperitoneally 1.8mg/kg/day of cisplatin for periods of 3, 5, 7 and 9 days. On the next day, 99mTc-DMSA uptake and Ccr were measured. Ccr of 5-day treated group was significantly lower than that of control (0.13 +- 0.10 vs 0.34 +- 0.05ml/min/100g; p<0.01) but 99mTc-DMSA uptake did not change. 99mTc-DMSA uptake of 7-day treated group was significantly lower than that of control (28.57 +- 7.23 vs 39.84 +- 2.23%; p<0.01). As the second experiment, cisplatin (3.6mg/kg/day) was given intraperitoneally on the 1st, 2nd, 15th and 16th day. On the 5th, 8th, 11th, 15th, 20th, 23rd, 26th and 30th day, the same measurements were done as the first one. Ccr was lower in cisplatin treated rats on the 5th day than that in control (0.10 +- 0.03 vs 0.34 +- 0.05ml/min/100g; p<0.01), thereafter tended to be recovered to the control level. On the other hand, 99mTc-DMSA uptake was lower than that of control on the 8th, 11th and 15th day (32.40 +- 3.86, 32.56 +- 1.19, 35.21 +- 2.97 vs 39.84 +- 2.23%, respectively; p<0.01). The discrepancy between 99mTc-DMSA uptake and Ccr was observed in the cisplatin-induced nephrotoxicity. 99mTc-DMSA uptake was suggested to be a reliable indicator of a renal function in a different way from Ccr. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 99mTc-dimercaptosuccinic acid (99mTc-DMSA), Drug-induced nephrotoxicity, Cis-Dichlorodiammineplatinum (II) (CDDP), Absolute renal uptake. |
|---|